

Repositioning FDA-Approved Drugs in Combination with Epigenetic Drugs to Reprogram Colon Cancer Epigenome

Noël J.-M. Raynal, Elodie M. Da Costa, Justin T. Lee, et al.

Mol Cancer Ther 2017;16:397-407. Published OnlineFirst December 15, 2016.

Updated version	Access the most recent version of this article at: doi: 10.1158/1535-7163.MCT-16-0588
Supplementary Material	Access the most recent supplemental material at: http://mct.aacrjournals.org/content/suppl/2016/12/13/1535-7163.MCT-16-0588.DC1

Cited articles	This article cites 40 articles, 9 of which you can access for free at: http://mct.aacrjournals.org/content/16/2/397.full#ref-list-1
Citing articles	This article has been cited by 4 HighWire-hosted articles. Access the articles at: http://mct.aacrjournals.org/content/16/2/397.full#related-urls

E-mail alerts	Sign up to receive free email-alerts related to this article or journal.
Reprints and Subscriptions	To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org .
Permissions	To request permission to re-use all or part of this article, use this link http://mct.aacrjournals.org/content/16/2/397 . Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.